Norwegian clinical-stage company Oncoinvent has published two articles in special edition of Frontiers in Medicine focused on alpha radioisotopes. The first “Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis” describes a Phase 1 trial of 224Ra-CaCO3-MP injection in six patients with colorectal cancer. Whole-body gamma camera imaging, urine analysis and blood tests allowed for effective radiation dose limits for hospital workers, carers and the public to be set. The next paper, “First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)”, enrolled patients with increasing activity doses of 1 to 7 over 30 days. Oncoinvent CEO Jan A. Alfheim said the publications showed “all dose levels of Radspherin® are well tolerated with no dose limiting toxicities to date”.

In Other News Around the World:

By Mark Smith

Mark Smith is a political commentator and analyst who has been covering politics for over 15 years. He has worked for major news networks and publications, and his insights into political campaigns and election results are highly valued. Mark's ability to break down complex political issues and explain them in a way that is easy to understand has made him a popular figure among audiences.

Leave a Reply

Your email address will not be published. Required fields are marked *